18β-Glycyrrhetinic acid

SKU: orb1310997

Description

18β-Glycyrrhetinic acid (Enoxolone) is the principal active compound derived from licorice root, known for its anti-ulcerative, anti-inflammatory, and antiproliferative activities. It is widely used in research involving inflammation, cancer cell proliferation, and gastrointestinal studies, with applications in both in vitro and in vivo experimental models.

Research Area

Metabolism Research

Key Properties

• CAS Number: 471-53-4
• MW: 470.68
• Purity: 99.03% (May vary between batches)
• Formula: C₃₀H₄₆O₄
• SMILES: C[C@]12[C@@]([C@]3(C)[C@@](CC1)(C(C)(C)[C@@H](O)CC3)[H])(C(=O)C=C4[C@@]2(C)CC[C@]5(C)[C@]4(C[C@](C(O)=O)(C)CC5)[H])[H]
• Target: Endogenous Metabolite,Dehydrogenase
• Solubility: DMSO:252.5 mg/mL (536.46 mM);10% DMSO+40% PEG300+5% Tween 80+45% Saline:2 mg/mL (4.25 mM);H2O:< 1 mg/mL (insoluble or slightly soluble);Ethanol:< 1 mg/mL (insoluble or slightly soluble)

Bioactivity

• In Vivo:
  Rats in Enoxolone+Triptolide (TP) group which receive low-dose Enoxolone (50 mg/kg) have significant reductions in the three serum parameters when compare with TP rats. Rats in Enoxolone+TP group which receive the high-dose Enoxolone (100 mg/kg) have slightly lowered the levels of three liver enzymes, the reductions do not reach statistical significance compare with TP group. Contrastingly, preadministration of low-dose Enoxolone protects animals from TP-induced hepatic lesions. On the contrary, low-dose Enoxolone (50 mg/kg) markedly suppresses the release of the four cytokines above.
• In Vitro:
  MTS assay demonstrates that 24 h treatment of Enoxolone suppresses cell proliferation in both cell lines in a dose-dependent manner. Enoxolone at 160 μM significantly decreases the percentage of viable cells to around 40.5±10.5% in A549 and 38.3±4.6% in NCI-H460 (p<0.01 respectively). When the cells are treated with 320 μM Enoxolone, a greater inhibitory effects on cell proliferation is shown, as the percentage of viable cells is below 30% compare with untreated controls (p<0.001). Treatment with Enoxolone at 160 μM and 320 μM decreases the levels of full-length PARP and increases the levels of cleaved-PARP.

Storage & Handling

• Storage: -20°C
• Expiration Date: 12 months from date of receipt.
• Disclaimer: For research use only

Alternative Names

Dehydrogenase, 18beta-Glycyrrhetinic acid, 18b-Glycyrrhetinic acid, 18β Glycyrrhetinic acid, 18βGlycyrrhetinic acid, 18β-Glycyrrhetinic acid, inhibit, Enoxolone, Endogenous Metabolite, EndogenousMetabolite, Glycyrrhetin, Inhibitor

Compound Identifiers

PubChem CID

9897771